Artificial Intelligence
Digital Pathology Market Size & Share Worth $1.89Bn, Globally, by 2028 Growing at 12.1% CAGR | Exclusive Report by The Insight Partners
New York, Aug. 18, 2022 (GLOBE NEWSWIRE) — The Insight Partners published latest research study on “Digital Pathology Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by product, type, application, end user, and geography,” the report highlights trends prevailing in the market and factors driving its growth. The growth of the digital pathology market is attributed to the rising adoption of digital pathology to enhance lab efficiency and growing applications of digital pathology in drug development and companion diagnostics. However, the high cost of digital pathology systems and the shortage of skilled professionals to operate these systems may hinder the market growth.
Get Sample PDF Copy of Digital Pathology Market Size – COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.theinsightpartners.com/sample/TIPHE100000855/
Digital Pathology Market Report Scope & Strategic Insights:
| Report Coverage | Details |
| Market Size Value in | US$ 0.95 Billion in 2022 |
| Market Size Value by | US$ 1.89 Billion by 2028 |
| Growth rate | CAGR of 12.1% from 2022 to 2028 |
| Forecast Period | 2022-2028 |
| Base Year | 2022 |
| No. of Pages | 226 |
| No. Tables | 197 |
| No. of Charts & Figures | 83 |
| Historical data available | Yes |
| Segments covered | Product, Type, Application, and End User |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country scope | US, UK, Canada, Germany, France, Italy, Australia, Russia, China, Japan, South Korea, Saudi Arabia, Brazil, Argentina |
| Report coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Digital Pathology Market: Competitive Landscape and Key Developments
Koninklijke Philips N.V.; Nikon Corporation; Perkin Elmer, Inc.; Indica Labs; 3DHISTECH Ltd.; Hamamatsu Photonics K.K.; F. Hoffmann-La Roche Ltd; Visiopharm A/S; Glencoe Software, Inc.; and Danaher Corporation are among the leading companies in the digital pathology market. The market is anticipated to flourish with the development of new innovative products by market players.
Inquiry Before Purchase: https://www.theinsightpartners.com/inquiry/TIPHE100000855/
In October 2021, Koninklijke Philips N.V. launched its next-generation digital pathology solution—IntelliSite—to assist pathologists in diagnosing and creating care pathways.
In July 2021, Danaher Corporation announced its next-generation Aperio GT 450 DX scanner that supports DICOM Imaging and shows compatibility with PACS; the product enables the tighter integration of digital pathology imaging into diagnostic pathway.
In June 2020, Koninklijke Philips N.V. collaborated with Proscia to accelerate and encourage the adoption of digital pathology in laboratories. The agreement provides Proscia an exclusive right to natively utilize Philips’ iSyntax image format with its Concentriq digital pathology platform.
In April 2021, Koninklijke Philips N.V. collaborated with Ibex to promote their digital pathology and artificial intelligence (AI) solutions to hospitals, health networks, and pathology labs across the world. This helped the company to provide objective, reproducible results, and boost diagnostic confidence.
Have a question? Speak to Research Analyst: https://www.theinsightpartners.com/speak-to-analyst/TIPHE100000855
In April 2021, Danaher Corporation entered into a partnership with Paige to expand its access to computational pathology products for clinical and translational research. The agreement brings Paige’s AI-enabled research software for tumor detection, grading, and quantification to Leica Biosystems’ digital pathology platform in North American and European countries.
The North America digital pathology market is further segmented into the US, Canada, and Mexico. The market growth in the region is attributed to the growing number of initiatives to promote the use of digital pathology for enhanced disease diagnosis and advanced pathology practice. The US Food and Drug Administration (FDA) has provided clearance for the use of digital pathology and whole slide imaging (WSI) systems in primary diagnosis. In April 2017, the first WSI system for digital pathology was approved for primary diagnostics in the US. This has helped pathologists in digitizing the workflow, and in gathering, storing, and transferring patent data from remote places. The second digital pathology system was authorized for marketing in the US in 2019. As a result, 100% of labs in the US are likely to go digital in the near future. The FDA approval of WSI systems has allowed research institutes in the US to increase their efficiency and workflow. The American Cancer Society (ACS) estimated 1,898,160 new cancer cases and 608,570 cancer-related deaths in the US in 2021. Digital pathology solutions play a vital role in cancer diagnosis and drug discovery, which supports the market growth in North America.
Use of Digital Pathology in Cancer Diagnosis Boosts Market Growth:
The World Health Organization (WHO) has reported cancer as the first leading cause of death in people of age less than 70 in 183 countries and the fourth leading cause of death among the population of all ages in 123 countries worldwide in 2019. In addition, as per the data published by the WHO in March 2021, different cancer types caused ~10 million deaths in 2020 in the world. The use of digital pathology allows the in-depth diagnosis of tumors. Traditional pathology services can only help locate the tumor cells, which makes it difficult to share the cases for a second review. Digital cancer diagnosis typically involves scanning conventional glass slides to get successive images that are digitally united into a single, whole image that replicates information on the glass slide. The pictures from associated clinics/hospitals or labs are combined to provide an integrated picture of each unique cancer condition to the pathologists.
Avail Lucrative DISCOUNTS on “Digital Pathology Market” Research Study: https://www.theinsightpartners.com/discount/TIPHE100000855/
Companies are launching new digital pathology tools and technologies for cancer detection. In January 2021, Roche launched the CE-IVD automated digital pathology algorithms that are capable of uPath HER2 Dual ISH image analysis and uPath HER2 (4B5) image analysis for breast cancer diagnosis, which also helps healthcare providers determine the best treatment strategy for each patient. Artificial intelligence (AI) is used in image analysis algorithms to assist pathologists in achieving quick and accurate patient diagnoses. Further, in May 2022, Hartford HealthCare launched a clinical research and innovation platform in collaboration with Ibex Medical Analytics, a pioneer in AI-powered cancer diagnostics, to help clinicians deliver accurate diagnoses and enhanced care for patients with breast cancer. Thus, the use of digital solutions in the diagnosis of cancer is increasing with technological developments, thereby fueling the digital pathology market growth.
Digital Pathology Market: Segmental Overview
Based on product, the digital pathology market is segmented into scanner, software, storage, and communication systems. The scanner segment is further bifurcated into integrated and standalone. The scanner segment held the largest market share in 2021; however, the software segment is expected to register the highest CAGR during the forecast period.
Based on type, the digital pathology market is bifurcated into human pathology and veterinary pathology. The human pathology segment held a larger market share in 2021 and is expected to register a higher CAGR during the forecast period.
Based on application, the digital pathology market is segmented into drug discovery, disease diagnostics, teleconsultation, and training & education. The drug discovery segment held the largest market share in 2021 and is expected to register the highest CAGR during the forecast period.
Directly Purchase Premium Copy of Digital Pathology Market Growth Report at: https://www.theinsightpartners.com/buy/TIPHE100000855/
Based on end user, the digital pathology market is segmented into pharma & biotech companies, hospitals, and academics. The pharma & biotech companies segment held the largest market share in 2021 and is estimated to register the highest CAGR during the forecast period.
Browse Adjoining Reports:
Pathology Devices Market Forecast to 2028 – Covid-19 Impact and Global Analysis – By Technology (Immunoassays Technology, Disease Diagnostics, Clinical Chemistry, Drug Discovery and Development, Forensic Diagnostics); Application (Clinical Chemistry, Hematology, Immunoassays Technology, Microbiology, Molecular Diagnostics); End User (Diagnostics laboratories, Forensic Laboratories, Academic Institutes, Contract Research Organizations, Pharmaceutical and Biotechnology Companies) and Geography
Anatomic Pathology Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Product and Service (Instruments, Consumables, and Services), Application (Disease Diagnosis, Drug Discovery and Development, and Others), and End User (Hospitals, Research Laboratories, Diagnostic Laboratories, and Others) and Geography
Whole Slide Imaging Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Hardware, Software, and Service), Application (Telepathology, Cytopathology, Immunohistochemistry, and Hematopathology), and End User (Hospital, Pharmaceutical and Biopharmaceutical Companies, Laboratories, and Academic Research Institute)
Histology and Cytology Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Cytology, Histology); Test Type (Microscopy Tests, Molecular Genetics Tests, Flow Cytomtery); End User (Hospitals/Clinics, Biopharmaceutical Companies, Academia, Other End Users)
Diagnostic Labs Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Lab Type (Single/Independent Laboratories, Hospital-Based Labs, Physician Office Labs, And Others), Testing Services [Physiological Function Testing (ECG, Echo, X-ray, Endoscopy, CT, MRI, and Others), General and Clinical Testing, Esoteric Testing, Specialized Testing, Non-invasive Prenatal Testing, COVID-19 Testing, and Others], Revenue Source (Healthcare Plan Operators and Insurers, Out-of-Pocket, and Public System)
Molecular Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Disease Area (Oncology, Infectious diseases, Genetic testing, Cardiac diseases, Immune system disorders, and Others); Technology (Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and Next-Generation Sequencing (NGS), In Situ Hybridization, DNA Microarray, and Others); Product and Services (Assays and Kits, Instruments, Services and Software); End User (Hospitals and Clinics, Diagnostic Laboratories, Research and Academic Institutes, and Others) and Geography
Laboratory Developed Test Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Type (Clinical Biochemistry, Critical Care, Hematology, Microbiology, Molecular Diagnostics, Immunology, and Others) and Application (Academic Institutes, Clinical Research Organizations, Hospitals Laboratory, Specialty Diagnostic Centers, and Others)
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: [email protected]
Phone: +1-646-491-9876
Press Release: https://www.theinsightpartners.com/pr/digital-pathology-market
LONDON, May 1, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT; CLVT PR A) (“Clarivate”), a leading global provider of transformative intelligence, today announced that its board of directors declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares (the “Preferred Shares”), payable in cash on June 3, 2024 to shareholders of record at the close of business on May 15, 2024.
On the mandatory conversion date, which is scheduled to occur on June 3, 2024, each Preferred Share will automatically and mandatorily convert into a number of ordinary shares of Clarivate (and cash in lieu of any fractional ordinary shares) based on the average volume weighted average price (“VWAP”) of Clarivate’s ordinary shares over a 30-trading day period that begins on, and includes, April 18, 2024 and is scheduled to end on, and include, May 30, 2024 (the “valuation period”). If such VWAP is (i) greater than $31.20, then the mandatory conversion rate will be 3.2052 ordinary shares of Clarivate per Preferred Share, (ii) less than or equal to $31.20 but equal to or greater than $26.00, then the mandatory conversion rate will be a number of ordinary shares of Clarivate per Preferred Share equal to $100.00 divided by such VWAP and (iii) less than $26.00, then the mandatory conversion rate will be 3.8462 ordinary shares of Clarivate per Preferred Share. The mandatory conversion rate will be announced following the end of the valuation period. The above description of the terms of the Preferred Shares is not complete and is subject to, and qualified in its entirety by reference to, the “Statement of Rights” for the Preferred Shares, which is filed as Exhibit 3.2 to Clarivate’s annual report on Form 10-K for the fiscal year ended December 31, 2023.
Cautionary Note Regarding Forward-Looking Statements
This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management’s current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “see,” “seek,” “should,” “strategy,” “strive,” “target,” “will,” and “would” and similar expressions, and variations or negatives of these words. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed under the caption “Risk Factors” in our annual report on Form 10-K, along with our other filings with the U.S. Securities and Exchange Commission (“SEC”). However, those factors should not be considered to be a complete statement of all potential risks and uncertainties. Additional risks and uncertainties not known to us or that we currently deem immaterial may also adversely affect our business operations. Forward-looking statements are based only on information currently available to our management and speak only as of the date of this communication. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, except as otherwise required by securities and other applicable laws. Please consult our public filings with the SEC or on our website at www.clarivate.com.
About Clarivate
Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com.
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clarivate-declares-dividend-on-mandatory-convertible-preferred-shares-302133633.html
BEIJING, May 1, 2024 /PRNewswire/ — Focusing on the development of AI, the third CMG Forum was held on Monday in Beijing.
Li Shulei, a member of the Political Bureau of the Communist Party of China (CPC) Central Committee and the head of the Publicity Department of the CPC Central Committee, attended the opening of the event and delivered a speech.
Guests at the forum stressed the role of media in promoting the innovative application of AI as well as its governance.
Efforts should also be made to boost the development of AI in creating positive, healthy, diverse and high-quality content, so that AI can become a force for good and benefit mankind, they agreed.
They also called on media to accelerate intelligent transformation and help bridge international exchanges and cooperation on the governance of AI to facilitate its healthy, orderly and safe development.
Hosted by China Media Group (CMG), the forum attracted more than 200 participants from international organizations, media, think tanks and multinational companies.
“Innovation and breakthroughs in science and technology not only guide the development and progress of human civilization, but also bring uncertainty to the changing world,” said Shen Haixiong, vice minister of the Publicity Department of the CPC Central Committee and president of CMG. He called for efforts to jointly create valuable and responsible artificial intelligence.
AI technology is affecting every aspect of our lives. Thomas Bach, president of the International Olympic Committee (IOC), stated in a video speech that CMG has always been a partner of the IOC, bringing the charm of the Olympic Games to hundreds of millions of Chinese viewers. He said the IOC invites CMG to work together for the creation of a future with the application of AI in Olympic sports.
“From ancient inventions such as silk, printing and the compass to modern technological advances such as robotics, telecommunications and green technology, China has always been committed to innovation and creation,” said Daren Tang, director general of the World Intellectual Property Organization (WIPO). He said WIPO pays close attention to ensuring a balance between the opportunities and risks of artificial intelligence and is committed to strengthening cooperation to ensure that artificial intelligence is properly used.
https://news.cgtn.com/news/2024-04-30/3rd-CMG-Forum-in-Beijing-discusses-AI-development-1tdDcXvCexG/p.html
View original content:https://www.prnewswire.co.uk/news-releases/cgtn-3rd-cmg-forum-in-beijing-discusses-ai-development-302133410.html
Artificial Intelligence
Trianz Appoints Sridhar Kannan as Practice Leader – Digital, Elevating its Leadership in the Global Digital Transformation Space
SANTA CLARA, Calif., May 1, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Sridhar Kannan as Practice Leader – Digital. With over 25 years of extensive experience in technology and business leadership, Sridhar joins Trianz to lead the expansion of Trianz’s Digital Practice, forging strategic alliances and expanding the business footprint.
Sridhar’s appointment comes at a transformative phase for Trianz as it solidifies its commitment to redefining the digital landscape with an “IP Led” model. This strategic shift is powered by Trianz’s cutting-edge hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace. Sridhar’s visionary leadership in technology-led business transformations across diverse sectors will be instrumental in leveraging IP-led models and innovative methodologies to position Trianz at the forefront of digital transformation.
“We are thrilled to welcome Sridhar Kannan to the Trianz family,” said Seshi Vanguru, Chief Revenue Officer at Trianz. “His appointment marks a significant stride in Trianz’s journey toward innovation and excellence. Sridhar’s wealth of experience and exceptional leadership skills will elevate our Digital Practice to new heights, reaffirming our commitment to delivering exceptional value to our clients.”
Sridhar is recognized as a client-focused technology and business transformation executive with a remarkable track record of helping Banking and Financial Services organizations in business transformation and product innovation using applications, cloud, data, and digital solutions. His extensive prior experience at industry giants such as Wipro, Cognizant, and Infosys include successfully leading Fortune 10 global client relationships and implementing transformative solutions across Banking, Financial Services, and Healthcare industries. Sridhar is highly regarded for his ability to lead global cross-functional teams, foster collaboration, and achieve aggressive business goals while consistently delivering high levels of client satisfaction.
“I am deeply honored to join Trianz and contribute to its mission of shaping the future through digital transformation,” said Sridhar. “Together, we will push the boundaries of what’s possible and drive meaningful impact for our clients in this rapidly evolving digital landscape.”
Based out of Minnesota, US, Sridhar has steered numerous clients towards success through the strategic application of Digital, Cloud, Product Engineering, Data, AI, and Application services, making him a seasoned strategist in today’s dynamic digital landscape. His appointment marks a significant milestone in Trianz’s journey to nurturing talent and delivering world-class solutions.
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our “IP Led Transformations” approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media Team : [email protected]+1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/trianz-appoints-sridhar-kannan-as-practice-leader–digital-elevating-its-leadership-in-the-global-digital-transformation-space-302132835.html
-
Uncategorized7 days agoCherrypicks Partners with AWS DevAx Leading Cloud Technology Innovation for Hong Kong Enterprises
-
Artificial Intelligence6 days agoHikvision redefines urban mobility with AIoT-powered solutions at Intertraffic 2024
-
Artificial Intelligence5 days agoHITACHI ACQUIRES MA MICRO AUTOMATION OF GERMANY IN EFFORT TO ACCELERATE GLOBAL EXPANSION OF ROBOTIC SI BUSINESS IN THE MEDICAL AND OTHER FIELDS
-
Artificial Intelligence6 days agoWeb O.No: Metaverse and Web 3.0 stunted by internet chaos, warn 87% of business leaders
-
Artificial Intelligence6 days ago
Greater efforts urged on sci-tech cooperation
-
Artificial Intelligence5 days agoCognitive Security Market Projected to Reach $134.26 billion by 2030 – Exclusive Report by 360iResearch
-
Uncategorized6 days ago
Xiao-I Corporation to Announce Full Year 2023 Results
-
Artificial Intelligence5 days ago
IBM, Government of Canada, Government of Quebec Sign Agreements to Strengthen Canada’s Semiconductor Industry
